aTyr Pharma (ATYR) Leerink Global Healthcare Conference 2026 summary

Scientific and clinical innovation

• Translating tRNA synthetase biology into therapies for inflammation and fibrosis, focusing on novel mechanisms involving immune modulation.

• Lead candidate efzofitimod targets interstitial lung diseases (ILDs), especially sarcoidosis and scleroderma-related ILD, with a differentiated approach addressing both inflammation and fibrosis.

• Efzofitimod acts via Neuropilin-2 on macrophages, restoring immune balance without overt immunosuppression, and has been featured in a landmark publication.

• Pipeline includes another candidate, 0101, targeting fibrosis, expected to enter the clinic next year.

Clinical trial results and impact

• Phase III global trial of efzofitimod in sarcoidosis enrolled 268 patients across multiple continents, using a rigorous steroid taper protocol.

• Nearly 80% steroid reduction observed with efzofitimod, but placebo also showed unexpectedly high reductions, impacting statistical significance.

• Durable quality of life improvements and symptom relief were consistently observed, especially at higher doses, with significant benefits over existing therapies.

• Composite endpoints showed patients were over 2.5x more likely to be steroid-free and have improved lung symptoms on high-dose efzofitimod.

• Safety profile was favorable, with low rates of serious adverse events and good tolerability.

Regulatory and commercial outlook

• Upcoming FDA Type C meeting in mid-April will determine the regulatory path, with preparations for a potential new trial if required.

• EFZO-FIT data is influencing global treatment guidelines, leading to reduced steroid use in clinical practice.

• Scleroderma-related ILD trial is ongoing, with interim data showing promising skin symptom improvement; enrollment expected to complete in the first half of 2026.

• Financial position is strong, with over $80 million in cash reported at year-end, supporting ongoing and future trials.

• Operational experience and clinician relationships position the company well for efficient execution of future late-phase trials.